ERBB2 and breast carcinoma: Retrospective studies have shown response of BM to intravenous trastuzumab [73], and prospective trials assessing the efficacy of trastuzumab in the treatment of HER2-positive breast cancer BM are underway (NCT02571530 and NCT01325207).